Results 51 to 60 of about 27,626 (220)

In-vitro Antifungal Activities of Kombucha Tea Culture Supernatant Combined with Voriconazole against Vulvovaginal Candidiasis Clinical Isolates

Journal of Health Science and Medical Research (JHSMR), 2023
Objective: To investigate the antifungal activity of voriconazole, with and without Kombucha tea culture, against Candida strains isolated from vulvovaginal candidiasis.  Material and Methods: The study included 150 females, within child-bearing periods,
Rasha H. Bassyouni, Fatma AboElnaga Ahmed, Ahmed A. Ismaiel, Abdelsamie Abdelmoneim, Haitham Badran, Mazen A. El Zahry, Reham Ali Dwedar, Ahmed Ashraf Wegdan   +7 more
doaj   +1 more source

Influence of Inflammation on Voriconazole Metabolism [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT Voriconazole pharmacokinetics shows a large inter- and intrapatient variability. Inflammation is associated with changes in the expression of CYP isoenzymes. Here, we evaluated the influence of inflammation, marked by C-reactive protein (CRP) levels in blood, on the metabolism of voriconazole.
E. R. van den Heuvel, M. A. Encalada Ventura, Lambert F.R. Span, Jan-Willem C. Alffenaar, Geny M. M. Groothuis   +4 more
openaire   +4 more sources

A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation

Microorganisms, 2021
Background: Voriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Drug concentrations might be significantly influenced by the use of extracorporeal membrane oxygenation (ECMO).
Ruth Van Daele, Britt Bekkers, Mattias Lindfors, Lars Mikael Broman, Alexander Schauwvlieghe, Bart Rijnders, Nicole G. M. Hunfeld, Nicole P. Juffermans, Fabio Silvio Taccone, Carlos Antônio Coimbra Sousa, Luc-Marie Jacquet, Pierre-François Laterre, Eric Nulens, Veerle Grootaert, Haifa Lyster, Anna Reed, Brijesh Patel, Philippe Meersseman, Yves Debaveye, Joost Wauters, Christophe Vandenbriele, Isabel Spriet   +21 more
doaj   +1 more source

EUCAST Technical Note on voriconazole [PDF]

Clinical Microbiology and Infection, 2008
Contains fulltext : 70467.pdf (Publisher’s version ) (Closed access)
Rodriguez-Tudela, J.L., Donnelly, J.P., Arendrup, M.C., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Danaoui, E., Denning, D.W., Fegeler, W., Gaustad, P., Lass-Florl, C., Moore, C., Richardson, M., Schmalreck, A., Velegraki, J.A., Verweij, P.E.   +17 more
openaire   +4 more sources

A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model

Journal of Translational Medicine, 2018
Background Invasive pulmonary aspergillosis (IPA) is a life-threatening disease in immunosuppressed patients. Voriconazole is commonly used to prevent and treat IPA in the clinic, but the optimal prophylactic antifungal regimen is unknown.
Taotao Wang, Tao Zhang, Ti Meng, Ying Li, Lu Chen, Qianting Yang, Haiyan Dong, Jin’e Lei, Limei Chen, Yalin Dong   +9 more
doaj   +1 more source

Voriconazole-induced hypokalemia and hyponatremia and their correlations with voriconazole trough concentration

Di-san junyi daxue xuebao, 2020
Objective To investigate the incidence rates of voriconazole-induced hypokalemia and hyponatremia and their correlations with voriconazole trough concentration in the patients with lung invasive aspergillosis.
CHENG Lin, WENG Bangbi, XIANG Rongfeng, XIA Peiyuan   +3 more
doaj   +1 more source

Voriconazole‐Associated Periostitis: New Insights into Pathophysiology and Management

JBMR Plus, 2022
Voriconazole‐associated periostitis (VAP) is an underrecognized and unpredictable side effect of long‐term voriconazole therapy. We report two cases of VAP occurring in the post‐transplant setting: a 68‐year‐old lung transplant recipient who required ...
Michael J Bennett, Matthew I Balcerek, Edward AD Lewis, Roland LL Zhang, Caroline Bachmeier, Siok Tey, Steven Faux, Laila Girgis, Jerry R Greenfield, Syndia Lazarus   +9 more
doaj   +1 more source

Haemorrhagic cystitis following the administration of voriconazole in the treatment of central nervous system aspergillosis: a case report

Journal of International Medical Research, 2020
Central nervous system aspergillosis (CNS-A) is a rare and fatal fungal infection. Voriconazole is the recommended treatment for CNS-A. The therapeutic effect of voriconazole is good, but its use is limited due to adverse reactions.
Zhaohao Zeng, Hong Luo, Kunyu Huang, Lianfang Xue, Hui Liu, Xiaoting Li, Lu Wang, Haimei Cen, Wei Bi, Yu Zhang   +9 more
doaj   +1 more source

Association between voriconazole-induced visual hallucination and dopamine in an analysis of the food and drug administration (FDA) adverse event reporting system database

Scientific Reports
Voriconazole is a second-generation azole used to treat serious fungal infections. Visual hallucinations constitute a representative adverse event caused by voriconazole. However, its mechanism of action remains unclear. In patients with schizophrenia or
Hideo Kato, Chihiro Shiraishi, Mao Hagihara, Hiroshige Mikamo, Takuya Iwamoto   +4 more
doaj   +1 more source

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis

Frontiers in Pharmacology
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was associated with the CYP2C19 phenotype. However, the combined effects of CYP2C19
Jing Ling, Xuping Yang, Lulu Dong, Yan Jiang, Sulan Zou, Nan Hu   +5 more
doaj   +1 more source